Literature DB >> 12224972

Treatment of stage IA cutaneous T-Cell lymphoma with topical application of the immune response modifier imiquimod.

Karen Rebecca Suchin1, Jacqueline M Junkins-Hopkins, Alain H Rook.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12224972     DOI： 10.1001/archderm.138.9.1137

Source DB:  PubMed          Journal:  Arch Dermatol        ISSN： 0003-987X


× No keyword cloud information.
  21 in total

1.  Skin effector memory T cells do not recirculate and provide immune protection in alemtuzumab-treated CTCL patients.

Authors:  Rachael A Clark; Rei Watanabe; Jessica E Teague; Christoph Schlapbach; Marianne C Tawa; Natalie Adams; Andrew A Dorosario; Keri S Chaney; Corey S Cutler; Nicole R Leboeuf; Joi B Carter; David C Fisher; Thomas S Kupper
Journal:  Sci Transl Med       Date:  2012-01-18       Impact factor: 17.956

Review 2.  New targets of therapy in T-cell lymphomas.

Authors:  Jack Erter; Lapo Alinari; Kamruz Darabi; Metin Gurcan; Ramiro Garzon; Guido Marcucci; Mark A Bechtel; Henry Wong; Pierluigi Porcu
Journal:  Curr Drug Targets       Date:  2010-04       Impact factor: 3.465

Review 3.  Menus for managing patients with cutaneous T-cell lymphoma.

Authors:  Brian Poligone; Peter Heald
Journal:  Semin Cutan Med Surg       Date:  2012-03

4.  Synergistic enhancement of cellular immune responses by the novel Toll receptor 7/8 agonist 3M-007 and interferon-γ: implications for therapy of cutaneous T-cell lymphoma.

Authors:  Maria Wysocka; Noor Dawany; Bernice Benoit; Andrew V Kossenkov; Andrea B Troxel; Joel M Gelfand; Michael Kelly Sell; Louise C Showe; Alain H Rook
Journal:  Leuk Lymphoma       Date:  2011-10

Review 5.  Effects of Toll-like receptor signals in T-cell neoplasms.

Authors:  Cori Morrison; Maria R Baer; Dan P Zandberg; Amy Kimball; Eduardo Davila
Journal:  Future Oncol       Date:  2011-02       Impact factor: 3.404

Review 6.  Immunopathogenesis and therapy of cutaneous T cell lymphoma.

Authors:  Ellen J Kim; Stephen Hess; Stephen K Richardson; Sara Newton; Louise C Showe; Bernice M Benoit; Ravi Ubriani; Carmela C Vittorio; Jacqueline M Junkins-Hopkins; Maria Wysocka; Alain H Rook
Journal:  J Clin Invest       Date:  2005-04       Impact factor: 14.808

Review 7.  Multidisciplinary Management of Mycosis Fungoides/Sézary Syndrome.

Authors:  Sara Berg; Jennifer Villasenor-Park; Paul Haun; Ellen J Kim
Journal:  Curr Hematol Malig Rep       Date:  2017-06       Impact factor: 3.952

8.  Therapeutic Toll-like receptor agonists directly influence mouse and human T cell lymphoma cell viability and cytokine secretion.

Authors:  Angela Landrigan; Gloria Yiu; Kanika Agarwal; Paul J Utz
Journal:  Leuk Lymphoma       Date:  2011-09-13

Review 9.  In situ vaccination: Cancer immunotherapy both personalized and off-the-shelf.

Authors:  Linda Hammerich; Adam Binder; Joshua D Brody
Journal:  Mol Oncol       Date:  2015-11-10       Impact factor: 6.603

10.  Profile of differentially expressed Toll-like receptor signaling genes in the natural killer cells of patients with Sézary syndrome.

Authors:  Kelly C G ManfrereC; Marina P Torrealba; Denis R Miyashiro; Nátalli Z Pereira; Fabio S Y Yoshikawa; Luana de M Oliveira; Jade Cury-Martins; Alberto J S Duarte; José A Sanches; Maria N Sato
Journal:  Oncotarget       Date:  2017-09-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.